(Q39414529)

English

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

scientific article published on October 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 September 2017

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation (English)

1 reference

Europe PubMed Central

11 September 2017

0 references

irritable bowel syndrome

1 reference

based on heuristic

inferred from title

author name string

Müller-Lissner SA

1

1 reference

Europe PubMed Central

11 September 2017

Fumagalli I

2

1 reference

Europe PubMed Central

11 September 2017

Bardhan KD

3

1 reference

Europe PubMed Central

11 September 2017

Pace F

4

1 reference

Europe PubMed Central

11 September 2017

Pecher E

5

1 reference

Europe PubMed Central

11 September 2017

Nault B

6

1 reference

Europe PubMed Central

11 September 2017

Rüegg P

7

1 reference

Europe PubMed Central

11 September 2017

language of work or name

0 references

publication date

1 October 2001

1 reference

Europe PubMed Central

11 September 2017

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

11 September 2017

15

1 reference

Europe PubMed Central

11 September 2017

10

1 reference

Europe PubMed Central

11 September 2017

1655-1666

1 reference

Europe PubMed Central

11 September 2017

Review article: irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Irritable bowel syndrome in office-based practice in the United States

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Symptom differences in moderate to severe IBS patients based on predominant bowel habit

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Is rectal pain sensitivity a biological marker for irritable bowel syndrome: psychological influences on pain perception

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

The irritable bowel syndrome: review and a graduated multicomponent treatment approach

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

The serotonin 5-HT4 receptor. 2. Structure-activity studies of the indole carbazimidamide class of agonists

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Irritable bowel syndrome clinical trial design: future needs

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Colonic motility in humans--a growing understanding

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Treatment of chronic constipation with cisapride and placebo

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Long QT syndrome during high-dose cisapride

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2001.01094.X

21 January 2018

Identifiers

10.1046/J.1365-2036.2001.01094.X

1 reference

Europe PubMed Central

11 September 2017

1 reference

Europe PubMed Central

11 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39414529&oldid=1826527234"